DARE

#4544
Dare Bioscience, Inc. - Common Stock
1.4 4 USD
+0.06%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
1.44
1.44
Jahresspanne
1.14
3.78
Tagesänderung
+5.88%
Monatliche Änderung
-28.00%
6 month change
-12.73%
Jahresänderung
-12.73%
Vorheriger Schlusskurs
1.3 6
Open
1.4 4
Tief
1.4 4
High
1.4 4
Volumen
4
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Dare Bioscience, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Dare Bioscience, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Dare Bioscience, Inc. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
Dare Bioscience, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Dare Bioscience, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Dare Bioscience, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Dare Bioscience, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Dare Bioscience, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Dare Bioscience, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Dare Bioscience, Inc. current report, Q2 FY2026
8-K

Dare Bioscience, Inc. current report, Q1 FY2025

Full document

Business Context and Reporting Period

This Form 8-K filing by Daré Bioscience, Inc. (DARE) is dated February 13, 2025. The report addresses a critical corporate governance issue regarding the company's continued listing on the Nasdaq Capital Market.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding market capitalization.

Material Changes

  • Delisting Notice: On February 13, 2025, Nasdaq notified the Company that it failed to regain compliance with Nasdaq Listing Rule 5550(b)(2) by the February 10, 2025 deadline.
  • Compliance Failure: The Company did not meet the minimum market value of listed securities requirement of $35.0 million.
  • Current Status: The Company's common stock is now subject to delisting unless a hearing is requested and successful.

Guidance, Outlook, and Risks

  • Immediate Action: The Company intends to timely request a hearing before the Nasdaq Hearing Panel. This request will stay the delisting process pending the Panel's decision.
  • Timeline: Hearings are typically scheduled 30 to 45 days after the request, with decisions issued within 30 days of the hearing. However, the Company warns that timelines could be shorter than expected.
  • Uncertainty: There is no assurance that the Panel will grant an extension period or that the Company will regain compliance within any granted period.
  • Forward-Looking Statements: The filing cautions investors against placing undue reliance on the estimated timing of the hearing and decision.

Investor Verification Checklist

  • Verify the current market value of listed securities to assess the gap against the $35.0 million threshold.
  • Monitor the official Nasdaq website for the scheduled date of the Hearing Panel.
  • Review the Company's subsequent filings for the outcome of the hearing and any granted extension periods.
  • Check for any concurrent announcements regarding capital raising efforts intended to restore compliance.

Nachrichten